Extract Luspatercept is a recombinant fusion protein that binds ligands of the activin receptor type IIB (ACTRIIB), a member of the transforming growth factor (TGF)-β superfamily. This results in the inhibition of Smad2/3 signalling and enhances late-stage erythroid maturation. This biotherapy has been recently approved for the treatment of transfusion-dependent anaemia in adult patients with lower-risk myelodysplastic syndromes (MDS) [1]. In the phase 3 randomised controlled trial COMMANDS, dyspnoea was reported as an adverse event in 12% of patients receiving luspatercept compared to 7% in the epoetin alfa group including, respectively, 4% and 1% cases of grade 3 - 4 severity [2].
Extract Luspatercept is a recombinant fusion protein that binds ligands of the activin receptor type IIB (ACTRIIB), a member of the transforming growth factor (TGF)-β superfamily. This results in the inhibition of Smad2/3 signalling and enhances late-stage erythroid maturation. This biotherapy has been recently approved for the treatment of transfusion-dependent anaemia in adult patients with lower-risk myelodysplastic syndromes (MDS) [1]. In the phase 3 randomised controlled trial COMMANDS, dyspnoea was reported as an adverse event in 12% of patients receiving luspatercept compared to 7% in the epoetin alfa group including, respectively, 4% and 1% cases of grade 3 - 4 severity [2].